Eli Lilly & Co. vs. Protagonist Therapeutics, Inc
Eli Lilly & Co. and Protagonist Therapeutics, Inc are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | PTGX | |
|---|---|---|
| Market Cap | $1.09 trillion | $9.84 billion |
| Revenue (TTM) | — | $281.99 million |
| Net Income (TTM) | — | $82.91 million |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | PTGX | |
|---|---|---|
| P/E Ratio | — | 150.58 |
| Price / Book | — | 11.69 |
| Price / Sales | — | 34.88 |
LLY and PTGX split the valuation factors evenly.
Profitability
| LLY | PTGX | |
|---|---|---|
| Net Margin | — | 29.40% |
| Return on Equity | — | 9.85% |
LLY and PTGX split the profitability factors evenly.
Risk & Sentiment
| LLY | PTGX | |
|---|---|---|
| Short Interest | 1.29% | 0.63% |
PTGX leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, PTGX overview, PTGX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.